Clin2
NCT05940961Possibly a fitRecruiting

Inotuzumab for MRD-positive B-cell leukemia after transplant

ALLMRD-positiveHematopoietic Stem Cell Transplantation

Treatments studied

Inotuzumab Ozogamicin

Part of Blood & lymphatic, Cancer clinical trials.

This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
42 people
Ages
15 years to 65 years
Study type
Interventional

Who can take part

  • You are between 15 and 65 years old.
  • You have B-cell ALL that is CD22-positive.
  • Your leukemia has a positive “MRD recurrence” after transplant (or for Ph+ ALL, prior BCR::ABL1 medicine has failed).
  • Your general health is good enough to do daily activities (ECOG score less than 3).
  • You can expect to live at least 3 more months, and you do not have serious heart, lung, liver, or kidney problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06861348Not yet recruiting· Phase 2
Drug combo for B-cell leukemia that returned after transplant

This trial tests a drug called InO, sometimes given with donor immune cells, for people whose B-cell acute lymphoblastic leukemia or lymphoma came back after a prior stem cell transplant. The goal is to see if it works and is safe.

Hangzhou
NCT06985485Recruiting· Phase 2
Immunotherapy for older or frail B-ALL patients

This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.

Suzhou, Jiangsu
NCT03104491Recruiting· Phase 1/Phase 2
Inotuzumab after transplant for CD22-positive leukemia

This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.

Westwood, Kansas
NCT06427330Recruiting· Phase 2
Low-Dose Inotuzumab After Transplant to Prevent Leukemia Relapse

This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.

Tianjin
NCT01371630Recruiting· Phase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia

This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.

Houston, Texas
NCT04747912Recruiting· Phase 2
Chemotherapy-free early treatment for Ph+ ALL using inotuzumab

This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.

Chicago, Illinois

Hear when a new Hematopoietic Stem Cell Transplantation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.